Dupilumab, a human monoclonal antibody that blocks the IL-4 and IL-13 pathways of eosinophil recruitment, has shown a promising clinical response in patients with asthma and is now approved in the setting of COPD. Here, IL4 is linked to chronic obstructive pulmonary disease.